Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review
L Tagliaferri, V Lancellotta, B Fionda… - Human Vaccines & …, 2022 - Taylor & Francis
Melanoma is an extremely aggressive tumor and is considered to be an extremely
immunogenic tumor because compared to other cancers it usually presents a well …
immunogenic tumor because compared to other cancers it usually presents a well …
Neoadjuvant checkpoint immunotherapy and melanoma: the time is now
The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence
of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a …
of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a …
Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma
H Chi, G Peng, J Yang, J Zhang, G Song… - Frontiers in …, 2022 - frontiersin.org
Background Uveal melanoma (UVM) is the most common primary intraocular malignancy in
adults and is highly metastatic, resulting in a poor patient prognosis. Sphingolipid …
adults and is highly metastatic, resulting in a poor patient prognosis. Sphingolipid …
Evolution and modulation of antigen-specific T cell responses in melanoma patients
J Huuhtanen, L Chen, E Jokinen, H Kasanen… - Nature …, 2022 - nature.com
Analyzing antigen-specific T cell responses at scale has been challenging. Here, we
analyze three types of T cell receptor (TCR) repertoire data (antigen-specific TCRs, TCR …
analyze three types of T cell receptor (TCR) repertoire data (antigen-specific TCRs, TCR …
[HTML][HTML] Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Background Uveal melanoma (UM) is the most common intraocular malignancy in adults. In
contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and …
contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and …
Prognostic biomarkers in uveal melanoma: The status quo, recent advances and future directions
NJ Lamas, A Martel, S Nahon-Estève, S Goffinet… - Cancers, 2021 - mdpi.com
Simple Summary Although rare, uveal melanoma (UM) is the most common cancer that
develops inside adult eyes. The prognosis is poor, since 50% of patients will develop lethal …
develops inside adult eyes. The prognosis is poor, since 50% of patients will develop lethal …
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
H Shen, F Huang, X Zhang, OA Ojo, Y Li… - Nature …, 2022 - nature.com
Therapeutic resistance to immune checkpoint blockers (ICBs) in melanoma patients is a
pressing issue, of which tumor loss of IFN-γ signaling genes is a major underlying …
pressing issue, of which tumor loss of IFN-γ signaling genes is a major underlying …
Uveal melanoma pathobiology: Metastasis to the liver
P Bustamante, L Piquet, S Landreville… - Seminars in cancer …, 2021 - Elsevier
Uveal melanoma (UM) is a type of intraocular tumor with a propensity to disseminate to the
liver. Despite the identification of the early driver mutations during the development of the …
liver. Despite the identification of the early driver mutations during the development of the …
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma
T Yao, Z Zhang, Q Li, R Huang, Y Hong, C Li… - Cancer Immunology …, 2023 - AACR
Tumor-specific neoepitopes are promising targets in cancer immunotherapy. However, the
identification of functional tumor-specific neoepitopes remains challenging. In addition to the …
identification of functional tumor-specific neoepitopes remains challenging. In addition to the …
Modern aspects of immunotherapy with checkpoint inhibitors in melanoma
V Petrova, I Arkhypov, R Weber, C Groth… - International Journal of …, 2020 - mdpi.com
Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-
tumor immune responses by exploiting tolerance mechanisms, including negative immune …
tumor immune responses by exploiting tolerance mechanisms, including negative immune …